COVID-19 With Convalescent Plasma

COVID-19 Convalescent Plasma Treatment Clinical Trial

Official title:

Efficiency of Convalescent Plasma Therapy in Management of Critically Ill Patients With COVID-19: a Matched Case-control Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04616976
• Other study ID #: COVID-19 convalescent plasma
• Status: Completed
• Start date: January 1, 2020
• Est. completion date: November 1, 2020

Study information

• Verified date: November 2020
• Source: Southeast University, China
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

To clarify the effects of convalescent plasma therapy on SARS-CoV-2 negative conversion rate during hospital stay and 28-day mortality of severe and life-threatening COVID-19 patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 78
• Est. completion date: November 1, 2020
• Est. primary completion date: February 29, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. > 18 years of age;

2. laboratory-confirmed diagnosis of COVID-19;

3. respiratory failure requiring advanced respiratory support (i.e. high flow nasal cannula[HFNC], noninvasive mechanical ventilation [NIV], and invasive mechanical ventilation [IMV]).

Exclusion Criteria:

• no

Related Conditions & MeSH terms

• COVID-19 Convalescent Plasma Treatment

Intervention

Biological:
• convalescent plasma
convalescent plasma was get from the patients who recovery from COVID-19

Locations

Country	Name	City	State
China	Zhongda Hospital, Southeast University	Nanjing	Jiangsu

Sponsors (1)

Lead Sponsor	Collaborator
Southeast University, China

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	28-day mortality	the mortality from ICU admission to 28 days after admission	28 days
Secondary	SARS-CoV-2 negative conversion rate	SARS-CoV-2 viral shedding	up to 60 days